Next, we confirmed that the EZH2-TPH1-5-HT7 axis is a useful therapeutic target against drug-resistant pancreatic cancer, using an in vivo tumor model in which PANC-1 cells were subcutaneously transplanted. This evidence concerns the gene TPH1 and pancreatic neoplasm.